PTHS — Pelthos Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $92.66m
- $110.32m
- $16.80m
Annual cashflow statement for Pelthos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.595 | -2.46 | -7.38 | -7.96 | -43.3 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -0.242 | 0.251 | 4.15 | 2.08 | 24.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.756 | 0.641 | 2.25 | 0.08 | -6.07 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.59 | -1.57 | -0.981 | -5.79 | -22.6 |
| Capital Expenditures | — | — | — | — | -8 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | — | 2.76 |
| Sale of Business | |||||
| Cash from Investing Activities | — | — | — | — | -5.24 |
| Financing Cash Flow Items | 1.59 | 1.22 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.59 | 1.62 | 1.02 | 6.21 | 45.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0 | 0.055 | 0.041 | 0.417 | 17.5 |